ABSTRACT
Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients, and the second leading cause of death in this setting. Cancer patients are also more likely to present recurrent VTE and major bleeding while taking anticoagulants. Management of VTE in these patients is always challenging and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cancer (ITAC-CME) released international guidelines for the treatment and prophylaxis of VTE and central venous catheter-associated thrombosis, based on a systematic review of the literature ranked according to the Grading of Recommendations Assessment, Development, and Evaluation scale. An update of these ITAC-CME consensus guidelines, including the use of direct oral anticoagulants, was recently published. In this review, we summarize these updated guidelines. Better adherence to the international guidelines, involving an adequate educational and active implementation strategies, will substantially decrease the burden of VTE and allow to increase survival in cancer patients.
Subject(s)
Neoplasms/complications , Smartphone , Venous Thromboembolism/etiology , Venous Thromboembolism/therapy , Humans , Internationality , Practice Guidelines as Topic , Venous Thromboembolism/prevention & controlABSTRACT
BACKGROUND: Imatinib mesylate is a potent inhibitor of platelet-derived growth factor and transforming growth factor-ß signalling pathways which may play a role in systemic sclerosis (SSc)-associated skin changes. OBJECTIVES: We aimed primarily at assessing the efficacy of imatinib mesylate in scleroderma skin fibrosis. METHODS: We performed a phase II double-blinded trial on patients with scleroderma with either morphoea involving > 20% of body surface area or SSc with extensive skin involvement: modified Rodnan Skin Score (mRSS) ≥ 20/51. Each patient was randomized to receive either imatinib mesylate 400 mg or placebo daily for a total of 6 months, and then was followed up 6 months after therapy discontinuation. Skin fibrosis was assessed by mRSS and measurement of the dermal thickness using skin biopsies performed at inclusion and at 6 months of treatment. In addition, quality of life (Dermatology Life Quality Index and modified Health Assessment Questionnaire for Scleroderma) was recorded at each visit, and pulmonary function before and after intervention. RESULTS: Twenty-eight patients were included in the study with a mean age of 48·9 years (range 30-71): 25 had a diagnosis of a SSc and three of diffuse cutaneous scleroderma. Demographic data, frequency of organ involvement of SSc and mRSS were comparable between groups. At 6 months, the proportion of variation of mRSS from inclusion was not statistically significantly different between the two groups (median +0·10 in imatinib group vs. -0·16 in placebo group, P = 0·098). Similarly, changes in dermal thickness, quality of life and diffusion capacity for carbon monoxide were not significantly different between groups. CONCLUSIONS: This study failed to demonstrate the efficacy of imatinib 400 mg daily to improve skin fibrosis of diffuse scleroderma after 6 months of treatment based on validated outcome measurements.
Subject(s)
Piperazines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Scleroderma, Diffuse/drug therapy , Skin/pathology , Adult , Aged , Benzamides , Double-Blind Method , Female , Fibrosis/drug therapy , Humans , Imatinib Mesylate , Male , Middle Aged , Platelet-Derived Growth Factor/metabolism , Quality of Life , Scleroderma, Diffuse/metabolism , Transforming Growth Factor beta/metabolism , Treatment OutcomeABSTRACT
A 73-year-old man with an urothelial carcinoma treated with gemcitabine and carboplatinium and an 84-year-old man with a mesothelioma treated with gemcitabine alone developed digital ischemia. In the first patient, the ischemia involved all fingers except the thumbs during the second cycle of treatment. The ischemia developed during the first cycle in the second patient and involved the right major and ring fingers. In the literature, gemcitabine vascular toxicity is probably potentialized by platinium salts. Several nosological entities occur simultaneously. The most widely described involve isolated digital ischemia for doses to the order of 3000mg, and a hemolytic and uremic thrombotic microangiopathy for gemcitabine doses above 10,000mg. The vascular toxicity of platinium salts is not dose-dependent. In these two patients, the clinical course was favorable with interruption of the chemotherapy, treatment by iloprost and aspirin.
Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Deoxycytidine/analogs & derivatives , Fingers/blood supply , Ischemia/chemically induced , Aged , Aged, 80 and over , Deoxycytidine/adverse effects , Humans , Male , GemcitabineSubject(s)
Tomography, X-Ray Computed , Vena Cava, Inferior/diagnostic imaging , Venous Thrombosis/diagnostic imaging , Adenocarcinoma, Clear Cell/blood , Adenocarcinoma, Clear Cell/diagnostic imaging , Adenocarcinoma, Clear Cell/drug therapy , Adenocarcinoma, Clear Cell/secondary , Aged, 80 and over , Angiogenesis Inhibitors/therapeutic use , Fibrinolytic Agents/therapeutic use , Heart Atria/diagnostic imaging , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Image Processing, Computer-Assisted , Indoles/therapeutic use , Kidney Neoplasms/surgery , Liver Neoplasms/blood , Liver Neoplasms/complications , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Male , Nephrectomy , Postoperative Complications/blood , Postoperative Complications/diagnostic imaging , Pyrroles/therapeutic use , Recurrence , Sunitinib , Thrombectomy , Tinzaparin , Vena Cava, Inferior/surgery , Venous Thrombosis/drug therapy , Venous Thrombosis/etiology , Venous Thrombosis/surgeryABSTRACT
OBJECTIVE: The objectives of this article are to review the data about the consequences of thrombophilia testing and to think about its indications. CURRENT KNOWLEDGE AND KEY POINTS: The indications of congenital thrombophilic testing have extended since the discovery of prevalent abnormalities, such as mutations of factor V or II genes. However, thrombophilia does not result in a significant increase in the risk of recurrence unlike the spontaneous occurrence of thrombotic events. The factor V Leiden mutation is associated with a moderate increase in recurrence rate, while the G20210A mutation of factor II is not associated with a significant increase in recurrence. Regarding the decrease in natural anticoagulants is concerned, there is no definite conclusion, although the decrease in antithrombin is suspected of being associated with an increase in recurrence. FUTURE PROSPECTS AND PROJECTS: Finally, identification of a constitutional thrombophilia most often do not influence the therapeutic decisions unless some rare abnormalities are found, such as a decrease in antithrombin, homozygous mutations in factors V or II genes or associations of thrombophilia. One must remember that antiphospholipid antibodies must be searched because their impact on recurrences is well-known. Diagnostic work-up for thrombophilia is not useful after a distal or a superficial venous thrombosis (except for antiphospholipid antibodies in case of distal venous thrombosis).
Subject(s)
Antithrombins/deficiency , Thrombophilia/diagnosis , Thrombophilia/therapy , Venous Thromboembolism/etiology , Antibodies, Antiphospholipid/blood , Antithrombins/genetics , Factor V Deficiency/genetics , Humans , Immunologic Factors/blood , Mass Screening , Mutation , Prothrombin/genetics , Secondary Prevention , Thrombophilia/complications , Thrombophilia/genetics , Thrombophilia/immunologyABSTRACT
We report a case of a retroperitoneal hematoma occurring in a patient under anticoagulation therapy for deep-venous thrombosis and presenting as an anuric acute renal failure. A coexisting polycythemia vera led to misdiagnosis that could have been life-threatening. A woman, known for polycythemia vera and a single functioning right kidney, was admitted with mild abdominal pain in a context of recent deep venous thrombosis under low-molecular weight heparin. Clinical examination revealed hepatomegaly associated with polycythemia vera. Biochemical evaluation disclosed an acute renal failure, and renal ultrasonography showed no dilation of the renal pelvis. Retroperitoneal hematoma resulted in shock, progressive anemia and obstructive renal failure, related to renal pelvic compression. A right renal indwelling catheter was introduced to restore urine flow after one hemodialysis session, and an inferior vena cava filter was placed because of anti-coagulation contra-indication. However, pulmonary embolism occurred, so that oral anticoagulants were introduced. The hematoma resorbed spontaneously, and a year after this episode, the patient is still alive and well. Retroperitoneal hematoma is a rare cause of obstructive acute renal failure and a life-threatening complication of anti-coagulation therapy.
Subject(s)
Acute Kidney Injury/etiology , Hematoma/complications , Ureteral Obstruction/complications , Acute Kidney Injury/therapy , Aged , Anticoagulants/adverse effects , Female , Hematoma/chemically induced , Hematoma/diagnostic imaging , Humans , Kidney Pelvis/diagnostic imaging , Kidney Pelvis/pathology , Polycythemia Vera/complications , Renal Dialysis , Retroperitoneal Space/diagnostic imaging , Retroperitoneal Space/pathology , Tomography, X-Ray Computed , Ureteral Obstruction/diagnostic imagingABSTRACT
Interferon alpha (IFN-alpha) is used to treat chronic myelogenous leukaemia (CML) patients. However, its target(s) remain(s) unknown. One possibility is that there is a differing sensitivity of the leukaemic from the normal colony-forming cell (CFC) compartments to IFN-alpha. Co-cultures of progenitors with stromal cells provide a valuable tool to dissect direct and indirect activities of IFN-alpha. In this study, we have used endothelial cells (EC) as a source of stromal cells. In co-cultures of normal progenitors with EC, IFN-alpha increased the generation of clonogenic cells, mainly via an increased production of flt3 ligand (FL) by EC. In contrast, in co-cultures of CML progenitors with EC, IFN-alpha inhibited the generation of clonogenic cells, mainly by direct inhibition on the progenitors, the up-regulation of FL production by stromal cells being unable to compensate for the direct inhibitory effects of IFN-alpha. These data provide evidence for a differential effect of IFN-alpha on the growth of CML and normal CFC cells in a stromal context and suggest that an alteration in the response of CML progenitor cells to FL is important in the explanation of this differential effect.
Subject(s)
Hematopoietic Stem Cells/metabolism , Interferon-alpha/pharmacology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Membrane Proteins/metabolism , Antigens, CD34/immunology , Cell Adhesion , Cell Culture Techniques/methods , Clone Cells/drug effects , Coculture Techniques , Endothelium/metabolism , Enzyme-Linked Immunosorbent Assay/methods , Flow Cytometry/methods , Hematopoietic Stem Cells/drug effects , HumansABSTRACT
CD40 ligand (CD40L)/CD40 interactions play a central role in T-cell-dependent B-cell activation as previously shown by in vitro studies, the phenotype of CD40L knockout mice and the defective expression of CD40L in patients who have X-linked immunodeficiency with hyper-IgM. The distribution of CD40 in cells other than of myeloid and lymphoid lineages has suggested additional functions for this receptor/ligand couple. Here we show that CD40L stimulates myelopoiesis with a noticeable effect on megakaryocytopoiesis in cocultures of hematopoietic progenitor cells and bone marrow stromal cells. These results suggest a mechanism by which T-cell or platelet-associated or soluble CD40L may regulate myelopoiesis. (Blood. 2000;95:3758-3764)
Subject(s)
Endothelium, Vascular/physiology , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/physiology , Leukopoiesis/physiology , Membrane Glycoproteins/pharmacology , Membrane Proteins/biosynthesis , Thrombopoietin/biosynthesis , Animals , Bone Marrow Cells/cytology , CD40 Ligand , COS Cells , Cells, Cultured , Coculture Techniques , Colony-Forming Units Assay , Endothelium, Vascular/cytology , Female , Fetal Blood/cytology , Hematopoietic Stem Cells/drug effects , Humans , Infant, Newborn , Leukopoiesis/drug effects , Mice , Mice, Knockout , Pregnancy , Umbilical VeinsABSTRACT
Flt3-ligand (FL) is a cytokine that is of paramount importance in the proliferation of primitive hematopoietic progenitors. In this study, we show that endothelial cells (EC) produce large amounts of soluble FL and express a membrane-bound form of the molecule. Bone marrow microvascular EC also produce FL, suggesting that EC are an important source of FL in the bone marrow. High concentrations of FL in EC supernatants contrast with its undetectable levels in long-term bone marrow cultures. A single mRNA for FL is detected, suggesting that soluble FL derives from the membrane-bound species by proteolytic release. FL mRNA is stable with a half-life of about 3 h. II-1alpha increases FL mRNA levels and membrane and soluble FL expression. Glucocorticoids, known inhibitors for many hematopoietic growth factors do not down-regulate the expression of FL. On the contrary, GC increase the expression of both species of FL. The neutralization of FL in cocultures EC/ hematopoietic progenitors results in an acceleration of the maturation of the progenitors. IFN-alpha, MIP-1 alpha and TGF-beta stimulate production of membrane-bound and soluble FL. This stimulation is essential to explain their modulatory effect on the generation of clonogenic cells in cocultures EC/hematopoietic progenitors. Leukemia (2000) 14, 153-162.
Subject(s)
Endothelium, Vascular/metabolism , Membrane Proteins/biosynthesis , Base Sequence , Bone Marrow Cells/cytology , Cell Differentiation , Cells, Cultured , Cloning, Molecular , Coculture Techniques , Cytokines/pharmacology , DNA Primers , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Glucocorticoids/pharmacology , Humans , Membrane Proteins/genetics , RNA, Messenger/genetics , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
We investigated the ability of endothelial cells (EC) to support hematopoiesis in contact and non-contact cocultures with isolated CD34+ or CD34/CD38low cells. In the absence of exogenous cytokines, umbilical vein EC (HUVEC) efficiently support proliferation of hematopoietic cells and generation of colony-forming cells (CFC). Cytokines (IL-6, LIF, G-CSF, GM-CSF, M-CSF, but not IL-1, IL-3, IL-7) were detected in HUVEC coculture supernatants. Neutralization of these cytokines profoundly inhibited the ability of EC supernatants to support the differentiation of hematopoietic progenitors and led to an accumulation of immature cells. Contact cocultures were significantly more efficient than non-contact cocultures. The expanded cell population essentially belonged to the myeloid and monocytic lineages. Contact cocultures generated cells expressing the CD61 or CD41 antigens. Interleukin-1alpha (IL-1alpha) augmented EC capacity to support hematopoiesis, this property resulting from the upregulation of cytokine expression. Glucocorticoids (GC) reduced this capacity by downregulating the biosynthesis of cytokines by EC and not by a direct effect on the progenitor cells. EC from the bone marrow microvasculature (BMEC) support the proliferation and the differentiation of hematopoietic progenitors. Synergistic increase in progenitor cells expansion and generation of CFC occurred when EC cocultures were added with exogenous cytokines. Supernatants of IL-1alpha-stimulated EC potentiated the effects of an association of IL-1, IL-3, IL-6, LIF, SCF, Flt3-ligand, TPO, G-CSF, GM-CSF, M-CSF and IL-11 on the proliferation of hematopoietic progenitors suggesting that EC may produce other soluble growth factors potentiating the action of the above set of cytokines.